RxDoctor Payments Data

Tien Nguyen, PA

Physician Assistant · San Francisco, CANPI 1306315502

Payments from drug & device makers

$1,579in general payments, 2019–2025

Across 51 payments — averaging $30.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$657
  • Astellas Pharma US Inc$291
  • Urovant Sciences Inc$268
  • E.r. Squibb & Sons, L.L.C.$177
  • Antares Pharma, Inc.$76
  • Boston Scientific$55
  • plus $54 from 3 others

What the payments were for

  • Travel & lodging$33921%
  • Food & beverage$1,18275%
  • Education$584%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,579 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$30,737
Medicare patients
241
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron127$124,190
MyrbetriqMirabegron133$114,935
Methenamine Hippurate146$11,109
Estradiol168$10,970
Trospium Chloride ErTrospium Chloride15$2,905
Trospium Chloride29$1,925
Potassium Citrate ErPotassium Citrate12$959
Tamsulosin Hcl60$956
Finasteride33$523
Solifenacin Succinate22$505
Oxybutynin Chloride ErOxybutynin Chloride16$503
Tobramycin Sulfate11$217
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$156
Cephalexin27$90
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$291$114,935133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →